Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 316-318

  Ritz, Nicole ^a,b,c   Tebruegge, Marc ^a,b,c   Connell, Tom G ^a,b,c   Sievers, Aina ^d   Robins Browne, Roy ^a,c   Curtis, Nigel ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; ERYTHROMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANTITUBERCULAR AGENTS; BCG VACCINE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM BOVIS;

EID: 59749089472     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01302-08     Document Type: Article

References (23)

1. Abe, C., I. Kobayashi, S. Mitarai, M. Wada, Y. Kawabe, T. Takashima, K. Suzuki, L. H. Sng, S. Wang, H. H. Htay, and H. Ogata. 2008. Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J. Clin. Microbiol. 46:2263-2268.
2. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. de Lisle, and W. R. Jacobs, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
3. Behr, M. A., M. A. Wilson, W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, and P. M. Small. 1999. Comparative genomics of BCG vaccines by wholegenome DNA microarray. Science 284:1520-1523.
4. Buriankova, K., F. Doucet-Populaire, O. Dorson, A. Gondran, J. C. Ghnassia, J. Weiser, and J. L. Pernodet. 2004. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob. Agents Chemother. 48:143-150.
5. Durek, C., S. Rusch-Gerdes, D. Jocham, and A. Bohle. 2000. Sensitivity of BCG to modern antibiotics. Eur. Urol. 37(Suppl. 1):21-25.
6. Goraya, J. S., and V. S. Virdi. 2001. Treatment of Calmette-Guerin bacillus adenitis: a metaanalysis. Pediatr. Infect. Dis. J. 20:632-634.
7. Hesseling, A. C., B. J. Marais, R. P. Gie, H. S. Schaaf, P. E. Fine, P. Godfrey-Faussett, and N. Beyers. 2007. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25:14-18.
8. Hesseling, A. C., H. Rabie, B. J. Marais, M. Manders, M. Lips, H. S. Schaaf, R. P. Gie, M. F. Cotton, P. D. van Helden, R. M. Warren, and N. Beyers. 2006. Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 42:548-558.
9. Hesseling, A. C., H. S. Schaaf, T. Victor, N. Beyers, B. J. Marais, M. F. Cotton, I. Wiid, R. P. Gie, P. van Helden, and R. M. Warren. 2004. Resistant Mycobacterium bovis bacillus Calmette-Guerin disease: implications for management of bacillus Calmette-Guerin disease in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 23:476-479.
10. Hok, T. T. 1964. A comparative study of the susceptibility to ethionamide, thiosemicarbazone, and isoniazid of tubercle bacilli from patients never treated with ethionamide or thiosemicarbazone. Am. Rev. Respir. Dis. 90:468-469.
11. Kruuner, A., M. D. Yates, and F. A. Drobniewski. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:811-818.
12. Lotte, A., O. Wasz-Hockert, N. Poisson, H. Engbaek, H. Landmann, U. Quast, B. Andrasofszky, L. Lugosi, I. Vadasz, P. Mihailescu, et al. 1988. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull. Int. Union Tuberc. Lung Dis. 63:47-59.
13. Mak, T. K., A. C. Hesseling, G. D. Hussey, and M. F. Cotton. 2008. Making BCG vaccination programmes safer in the HIV era. Lancet 372:786-787.
14. Rastogi, N., K. S. Goh, M. Berchel, and A. Bryskier. 2000. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J. Antimicrob. Chemother. 46:565-570.
15. Rastogi, N., K. S. Goh, M. Berchel, and A. Bryskier. 2000. In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob. Agents Chemother. 44:2848-2852.
16. Rastogi, N., K. S. Goh, A. Bryskier, and A. Devallois. 1996. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:1610-1616.
17. Ritz, N., W. A. Hanekom, R. Robins-Browne, W. J. Britton, and N. Curtis. 2008. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol. Rev. 32:821-841.
18. Rusch-Gerdes, S., G. E. Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 44:688-692.
19. Schaaf, H. S., D. P. Parkin, H. I. Seifart, C. J. Werely, P. B. Hesseling, P. D. van Helden, J. S. Maritz, and P. R. Donald. 2005. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Child. 90:614-618.
20. Shishido, Y., S. Mitarai, K. Otomo, M. Seki, A. Sato, I. Yano, A. Koyama, and T. Hattori. 2007. Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain. Int. J. Tuberc. Lung Dis. 11:1334-1338.
21. Turnbull, F. M., P. B. McIntyre, H. M. Achat, H. Wang, R. Stapledon, M. Gold, and M. A. Burgess. 2002. National study of adverse reactions after vaccination with bacille Calmette-Guerin. Clin. Infect. Dis. 34:447-453.
22. Wayne, L. G. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
23. World Health Organization. 2005. Isoniazid resistance of bacille Calmette-Guerin strains. Wkly. Epidemiol. Rec. 80:244.